EP3321276
Samrunaprótín til að meðhöndla efnaskiptakvilla
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
26.9.2012EP published:
28.7.2021EP application number:
17201957.2
EP translation filed:
28.9.2021Grant published:
15.10.2021EPO information:
European Patent Register
Max expiry date:
25.9.2032Expiry date:
25.9.2026Next due date:
30.9.2026
Title:
FUSION PROTEINS FOR TREATING METABOLIC DISORDERS
Timeline
Today
26.9.2012EP application
28.7.2021EP Publication
28.9.2021Translation submitted
15.10.2021Registration published
25.9.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
BOETTCHER, Brian R.Address:
Cambridge, MA 02139, US
Name:
CAPLAN, Shari L.Address:
Cambridge, MA 02139, US
Name:
DANIELS, Douglas S.Address:
Cambridge, MA 02139, US
Name:
HAMAMATSU, NorioAddress:
Cambridge, MA 02139, US
Name:
LICHT, StuartAddress:
Cambridge, MA 02139, US
Name:
WELDON, Stephen CraigAddress:
Cambridge, MA 02139, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201161539280 PDate:
26.9.2011Country:
US
Classification
Categories:
A61K 38/00, A61K 38/18, A61P 1/00, A61P 1/16, A61P 1/18, A61P 3/00, C07K 14/50, A61P 3/04, A61P 3/06, A61P 3/08, A61P 3/10, A61P 43/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 10.9.2021
Expires: 25.9.2022
Payer: G.H. Sigurgeirsson ehf.
Number: 11
Paid: 12.9.2022
Expires: 25.9.2023
Payer: G.H. Sigurgeirsson ehf.
Number: 12
Paid: 12.9.2023
Expires: 25.9.2024
Payer: G.H. Sigurgeirsson ehf.
Number: 13
Paid: 10.9.2024
Expires: 25.9.2025
Payer: G.H. Sigurgeirsson ehf.
Number: 14
Paid: 11.9.2025
Expires: 25.9.2026
Payer: G.H. Sigurgeirsson ehf.